Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 13, 2024
– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 –
– Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver topline data as anticipated in 2H 2025 –
Read more at globenewswire.com10.52
-0.02 (-0.19%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
